Fixed Phage secures further £1.5m investment to scale programmes in Animal, Veterinary and Human Health
Glasgow-based Biotechnology business, Fixed Phage, secures £1.5m follow-on investment to further scale development and commercialisation of bacteriophage technology in the fight against antimicrobial resistance.
The latest funding round has seen current investors, including Scottish Enterprise and London Scottish Investment Partners join a follow-on round to support the commercialisation of key programmes, which include the development and commercialisation of phage-based solutions in Animal & Veterinary health, as well as planning and development for Human health applications.
David Browning, CEO of Fixed Phage said: “The follow-on investment demonstrates how the company has continued to develop well-validated programmes leveraging robust phage technology, particularly in Animal & Veterinary health, with ambitious plans toward key programmes in human health. Underpinned by strong investor support to translate the technology to address antimicrobial resistance, the Company is well-positioned to develop, commercialise, and apply phage-based solutions to the market.”
Kerry Sharp, Director of Entrepreneurship and Investment at Scottish Enterprise, said: “We’ve supported Fixed Phage with both investment and grant support since its start-up stage, so it’s great to see the company continue its growth trajectory with this latest investment. It is a highly innovative company with strong growth prospects, as well as the ability to provide solutions to some of the world’s most pressing animal and human health concerns.”